{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:36:15Z","timestamp":1792892175439,"version":"4.5.0"},"reference-count":129,"publisher":"Aging and Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2020.1225","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T17:41:37Z","timestamp":1625334097000},"page":"1021","source":"Crossref","is-referenced-by-count":59,"title":["An Update on Medical and Surgical Treatments of Parkinson\u2019s Disease"],"prefix":"10.14336","volume":"12","author":[{"given":"Dipali","family":"Nemade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thyagarajan","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Shivkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2020.1225-1","doi-asserted-by":"crossref","unstructured":"Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. (2017). Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord, 32:1264-1310.","DOI":"10.1002\/mds.26904"},{"key":"key-10.14336\/AD.2020.1225-2","unstructured":"Collaborators GBDPsD (2018). Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol, 17:939-953."},{"key":"key-10.14336\/AD.2020.1225-3","doi-asserted-by":"crossref","unstructured":"Dorsey ER, Bloem BR (2018). The Parkinson Pandemic-A Call to Action. JAMA Neurol, 75:9-10.","DOI":"10.1001\/jamaneurol.2017.3299"},{"key":"key-10.14336\/AD.2020.1225-4","doi-asserted-by":"crossref","unstructured":"Deng H, Wang P, Jankovic J (2018). The genetics of Parkinson disease. Ageing Res Rev, 42:72-85.","DOI":"10.1016\/j.arr.2017.12.007"},{"key":"key-10.14336\/AD.2020.1225-5","doi-asserted-by":"crossref","unstructured":"Kouli A, Torsney KM, Kuan WL2018. Parkinson's Disease: Etiology, Neuropathology, and Pathogenesis. In Parkinson's Disease: Pathogenesis and Clinical Aspects. StokerTB, and GreenlandJC, editors. Brisbane (AU).","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"key":"key-10.14336\/AD.2020.1225-6","doi-asserted-by":"crossref","unstructured":"Kalinderi K, Bostantjopoulou S, Fidani L (2016). The genetic background of Parkinson's disease: current progress and future prospects. Acta Neurol Scand, 134:314-326.","DOI":"10.1111\/ane.12563"},{"key":"key-10.14336\/AD.2020.1225-7","doi-asserted-by":"crossref","unstructured":"Simon DK, Tanner CM, Brundin P (2020). Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med, 36:1-12.","DOI":"10.1016\/j.cger.2019.08.002"},{"key":"key-10.14336\/AD.2020.1225-8","doi-asserted-by":"crossref","unstructured":"Maillet A, Krack P, Lhommee E, Metereau E, Klinger H, Favre E, et al. (2016). The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain, 139:2486-2502.","DOI":"10.1093\/brain\/aww162"},{"key":"key-10.14336\/AD.2020.1225-9","doi-asserted-by":"crossref","unstructured":"Morris R, Martini DN, Madhyastha T, Kelly VE, Grabowski TJ, Nutt J, et al. (2019). Overview of the cholinergic contribution to gait, balance and falls in Parkinson's disease. Parkinsonism Relat Disord, 63:20-30.","DOI":"10.1016\/j.parkreldis.2019.02.017"},{"key":"key-10.14336\/AD.2020.1225-10","doi-asserted-by":"crossref","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H (2013). 100 years of Lewy pathology. Nat Rev Neurol, 9:13-24.","DOI":"10.1038\/nrneurol.2012.242"},{"key":"key-10.14336\/AD.2020.1225-11","doi-asserted-by":"crossref","unstructured":"Savica R, Carlin JM, Grossardt BR, Bower JH, Ahlskog JE, Maraganore DM, et al. (2009). Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology, 73:1752-1758.","DOI":"10.1212\/WNL.0b013e3181c34af5"},{"key":"key-10.14336\/AD.2020.1225-12","doi-asserted-by":"crossref","unstructured":"Cersosimo MG, Benarroch EE (2008). Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord, 23:1065-1075.","DOI":"10.1002\/mds.22051"},{"key":"key-10.14336\/AD.2020.1225-13","doi-asserted-by":"crossref","unstructured":"Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB (2019). Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. Brain, 142:2051-2067.","DOI":"10.1093\/brain\/awz111"},{"key":"key-10.14336\/AD.2020.1225-14","doi-asserted-by":"crossref","unstructured":"Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012). Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord, 27:716-719.","DOI":"10.1002\/mds.25020"},{"key":"key-10.14336\/AD.2020.1225-15","doi-asserted-by":"crossref","unstructured":"Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. (2012). Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord, 27:709-715.","DOI":"10.1002\/mds.23838"},{"key":"key-10.14336\/AD.2020.1225-16","doi-asserted-by":"crossref","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24:197-211.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"key-10.14336\/AD.2020.1225-17","doi-asserted-by":"crossref","unstructured":"Braak H, Del Tredici K (2017). Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis, 7:S71-S85.","DOI":"10.3233\/JPD-179001"},{"key":"key-10.14336\/AD.2020.1225-18","doi-asserted-by":"crossref","unstructured":"Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, et al. (2018). Does Parkinson's disease start in the gut? Acta Neuropathol, 135:1-12.","DOI":"10.1007\/s00401-017-1777-8"},{"key":"key-10.14336\/AD.2020.1225-19","doi-asserted-by":"crossref","unstructured":"Arotcarena ML, Dovero S, Prigent A, Bourdenx M, Camus S, Porras G, et al. (2020). Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain, 143:1462-1475.","DOI":"10.1093\/brain\/awaa096"},{"key":"key-10.14336\/AD.2020.1225-20","doi-asserted-by":"crossref","unstructured":"Angot E, Steiner JA, Hansen C, Li JY, Brundin P (2010). Are synucleinopathies prion-like disorders? Lancet Neurol, 9:1128-1138.","DOI":"10.1016\/S1474-4422(10)70213-1"},{"key":"key-10.14336\/AD.2020.1225-21","doi-asserted-by":"crossref","unstructured":"Dunning CJ, George S, Brundin P (2013). What's to like about the prion-like hypothesis for the spreading of aggregated alpha-synuclein in Parkinson disease? Prion, 7:92-97.","DOI":"10.4161\/pri.23806"},{"key":"key-10.14336\/AD.2020.1225-22","doi-asserted-by":"crossref","unstructured":"Goedert M (2015). NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science, 349:1255555.","DOI":"10.1126\/science.1255555"},{"key":"key-10.14336\/AD.2020.1225-23","doi-asserted-by":"crossref","unstructured":"Goedert M, Clavaguera F, Tolnay M (2010). The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci, 33:317-325.","DOI":"10.1016\/j.tins.2010.04.003"},{"key":"key-10.14336\/AD.2020.1225-24","doi-asserted-by":"crossref","unstructured":"Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med, 14:501-503.","DOI":"10.1038\/nm1746"},{"key":"key-10.14336\/AD.2020.1225-25","doi-asserted-by":"crossref","unstructured":"Olanow CW, Prusiner SB (2009). Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A, 106:12571-12572.","DOI":"10.1073\/pnas.0906759106"},{"key":"key-10.14336\/AD.2020.1225-26","doi-asserted-by":"crossref","unstructured":"Visanji NP, Brooks PL, Hazrati LN, Lang AE (2013). The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol Commun, 1:2.","DOI":"10.1186\/2051-5960-1-2"},{"key":"key-10.14336\/AD.2020.1225-27","doi-asserted-by":"crossref","unstructured":"Coughlin DG, Petrovitch H, White LR, Noorigian J, Masaki KH, Ross GW, et al. (2019). Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied. Parkinsonism Relat Disord, 64:124-131.","DOI":"10.1016\/j.parkreldis.2019.03.023"},{"key":"key-10.14336\/AD.2020.1225-28","doi-asserted-by":"crossref","unstructured":"Horsager J, Andersen KB, Knudsen K, Skjaerbaek C, Fedorova TD, Okkels N, et al. (2020). Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain, 143:3077-3088.","DOI":"10.1093\/brain\/awaa238"},{"key":"key-10.14336\/AD.2020.1225-29","doi-asserted-by":"crossref","unstructured":"Kong WL, Huang Y, Qian E, Morris MJ (2020). Constipation and sleep behaviour disorder associate with processing speed and attention in males with Parkinson's disease over five years follow-up. Sci Rep, 10:19014.","DOI":"10.1038\/s41598-020-75800-4"},{"key":"key-10.14336\/AD.2020.1225-30","doi-asserted-by":"crossref","unstructured":"Jankovic J (2008). Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry, 79:368-376.","DOI":"10.1136\/jnnp.2007.131045"},{"key":"key-10.14336\/AD.2020.1225-31","doi-asserted-by":"crossref","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord, 30:1591-1601.","DOI":"10.1002\/mds.26424"},{"key":"key-10.14336\/AD.2020.1225-32","doi-asserted-by":"crossref","unstructured":"Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al. (2008). Red flags for multiple system atrophy. Mov Disord, 23:1093-1099.","DOI":"10.1002\/mds.21992"},{"key":"key-10.14336\/AD.2020.1225-33","doi-asserted-by":"crossref","unstructured":"Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993). A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol, 50:140-148.","DOI":"10.1001\/archneur.1993.00540020018011"},{"key":"key-10.14336\/AD.2020.1225-34","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Okun MS (2020). Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 323:548-560.","DOI":"10.1001\/jama.2019.22360"},{"key":"key-10.14336\/AD.2020.1225-35","doi-asserted-by":"crossref","unstructured":"Leentjens AF (2015). Parkinson disease: Depression-risk factor or early symptom in Parkinson disease? Nat Rev Neurol, 11:432-433.","DOI":"10.1038\/nrneurol.2015.126"},{"key":"key-10.14336\/AD.2020.1225-36","doi-asserted-by":"crossref","unstructured":"Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L (2019). The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev, 43:37-46.","DOI":"10.1016\/j.smrv.2018.09.008"},{"key":"key-10.14336\/AD.2020.1225-37","doi-asserted-by":"crossref","unstructured":"Kim YE, Kim YJ, Hwang HS, Ma HI (2020). REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation. Parkinsonism Relat Disord, 80:120-126.","DOI":"10.1016\/j.parkreldis.2020.09.032"},{"key":"key-10.14336\/AD.2020.1225-38","doi-asserted-by":"crossref","unstructured":"Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, et al. (2018). The spectrum of \"off\" in Parkinson's disease: What have we learned over 40 years? Parkinsonism Relat Disord, 51:9-16.","DOI":"10.1016\/j.parkreldis.2018.02.001"},{"key":"key-10.14336\/AD.2020.1225-39","doi-asserted-by":"crossref","unstructured":"Deogaonkar M, Subramanian T (2005). Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease. Brain Res Brain Res Rev, 50:156-168.","DOI":"10.1016\/j.brainresrev.2005.05.005"},{"key":"key-10.14336\/AD.2020.1225-40","doi-asserted-by":"crossref","unstructured":"Lieu CA, Subramanian T (2012). The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesias. Brain Res Bull, 87:1-9.","DOI":"10.1016\/j.brainresbull.2011.09.013"},{"key":"key-10.14336\/AD.2020.1225-41","doi-asserted-by":"crossref","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, et al. (2018). Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol, 84:797-811.","DOI":"10.1002\/ana.25364"},{"key":"key-10.14336\/AD.2020.1225-42","doi-asserted-by":"crossref","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. (2014). The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain, 137:2731-2742.","DOI":"10.1093\/brain\/awu195"},{"key":"key-10.14336\/AD.2020.1225-43","doi-asserted-by":"crossref","unstructured":"Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM (2015). The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res, 5:12.","DOI":"10.1186\/s13550-015-0087-1"},{"key":"key-10.14336\/AD.2020.1225-44","doi-asserted-by":"crossref","unstructured":"Bajaj N, Hauser RA, Grachev ID (2013). Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry, 84:1288-1295.","DOI":"10.1136\/jnnp-2012-304436"},{"key":"key-10.14336\/AD.2020.1225-45","doi-asserted-by":"crossref","unstructured":"Ryman SG, Poston KL (2020). MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord, 73:85-93.","DOI":"10.1016\/j.parkreldis.2019.10.002"},{"key":"key-10.14336\/AD.2020.1225-46","doi-asserted-by":"crossref","unstructured":"Dhall R, Kreitzman DL (2016). Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety. Neurology, 86:S13-24.","DOI":"10.1212\/WNL.0000000000002510"},{"key":"key-10.14336\/AD.2020.1225-47","doi-asserted-by":"crossref","unstructured":"Trenkwalder C, Kuoppamaki M, Vahteristo M, Muller T, Ellmen J (2019). Increased dose of carbidopa with levodopa and entacapone improves \"off\" time in a randomized trial. Neurology, 92:e1487-e1496.","DOI":"10.1212\/WNL.0000000000007173"},{"key":"key-10.14336\/AD.2020.1225-48","doi-asserted-by":"crossref","unstructured":"Titova N, Levin O, Katunina E, Ray Chaudhuri K (2018). 'Levodopa Phobia': a review of a not uncommon and consequential phenomenon. NPJ Parkinsons Dis, 4:31.","DOI":"10.1038\/s41531-018-0067-z"},{"key":"key-10.14336\/AD.2020.1225-49","doi-asserted-by":"crossref","unstructured":"Mehanna R, Jankovic J (2019). Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord, 65:39-48.","DOI":"10.1016\/j.parkreldis.2019.06.001"},{"key":"key-10.14336\/AD.2020.1225-50","doi-asserted-by":"crossref","unstructured":"Espay AJ, Lang AE (2017). Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. JAMA Neurol, 74:633-634.","DOI":"10.1001\/jamaneurol.2017.0348"},{"key":"key-10.14336\/AD.2020.1225-51","doi-asserted-by":"crossref","unstructured":"Group PDMC, Gray R, Ives N, Rick C, Patel S, Gray A, et al. (2014). Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet, 384:1196-1205.","DOI":"10.1016\/S0140-6736(14)60683-8"},{"key":"key-10.14336\/AD.2020.1225-52","doi-asserted-by":"crossref","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. (2004). Levodopa and the progression of Parkinson's disease. N Engl J Med, 351:2498-2508.","DOI":"10.1056\/NEJMoa033447"},{"key":"key-10.14336\/AD.2020.1225-53","doi-asserted-by":"crossref","unstructured":"Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. (2019). Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. N Engl J Med, 380:315-324.","DOI":"10.1056\/NEJMoa1809983"},{"key":"key-10.14336\/AD.2020.1225-54","doi-asserted-by":"crossref","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, et al. (2013). Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol, 12:346-356.","DOI":"10.1016\/S1474-4422(13)70025-5"},{"key":"key-10.14336\/AD.2020.1225-55","doi-asserted-by":"crossref","unstructured":"Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. (2014). Randomized trial of IPX066, carbidopa\/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord, 20:142-148.","DOI":"10.1016\/j.parkreldis.2013.08.017"},{"key":"key-10.14336\/AD.2020.1225-56","doi-asserted-by":"crossref","unstructured":"Tambasco N, Romoli M, Calabresi P (2018). Levodopa in Parkinson's Disease: Current Status and Future Developments. Curr Neuropharmacol, 16:1239-1252.","DOI":"10.2174\/1570159X15666170510143821"},{"key":"key-10.14336\/AD.2020.1225-57","doi-asserted-by":"crossref","unstructured":"LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, et al. (2019). Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol, 18:145-154.","DOI":"10.1016\/S1474-4422(18)30405-8"},{"key":"key-10.14336\/AD.2020.1225-58","doi-asserted-by":"crossref","unstructured":"Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease PDMSI (2008). Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin, 24:2883-2895.","DOI":"10.1185\/03007990802387130"},{"key":"key-10.14336\/AD.2020.1225-59","doi-asserted-by":"crossref","unstructured":"Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, et al. (2011). Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology, 77:759-766.","DOI":"10.1212\/WNL.0b013e31822affb0"},{"key":"key-10.14336\/AD.2020.1225-60","doi-asserted-by":"crossref","unstructured":"Elshoff JP, Cawello W, Andreas JO, Mathy FX, Braun M (2015). An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Drugs, 75:487-501.","DOI":"10.1007\/s40265-015-0377-y"},{"key":"key-10.14336\/AD.2020.1225-61","doi-asserted-by":"crossref","unstructured":"Baig F, Kelly MJ, Lawton MA, Ruffmann C, Rolinski M, Klein JC, et al. (2019). Impulse control disorders in Parkinson disease and RBD: A longitudinal study of severity. Neurology, 93:e675-e687.","DOI":"10.1212\/WNL.0000000000007942"},{"key":"key-10.14336\/AD.2020.1225-62","doi-asserted-by":"crossref","unstructured":"Rabinak CA, Nirenberg MJ (2010). Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol, 67:58-63.","DOI":"10.1001\/archneurol.2009.294"},{"key":"key-10.14336\/AD.2020.1225-63","doi-asserted-by":"crossref","unstructured":"Nirenberg MJ (2013). Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging, 30:587-592.","DOI":"10.1007\/s40266-013-0090-z"},{"key":"key-10.14336\/AD.2020.1225-64","doi-asserted-by":"crossref","unstructured":"Dewey RBJr, Hutton JT, LeWitt PA, Factor SA (2001). A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol, 58:1385-1392.","DOI":"10.1001\/archneur.58.9.1385"},{"key":"key-10.14336\/AD.2020.1225-65","doi-asserted-by":"crossref","unstructured":"Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F (2017). Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease. Mov Disord Clin Pract, 4:78-83.","DOI":"10.1002\/mdc3.12350"},{"key":"key-10.14336\/AD.2020.1225-66","doi-asserted-by":"crossref","unstructured":"Olanow CW, Factor SA, Espay AJ, Hauser RA, Shill HA, Isaacson S, et al. (2020). Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol, 19:135-144.","DOI":"10.1016\/S1474-4422(19)30396-5"},{"key":"key-10.14336\/AD.2020.1225-67","doi-asserted-by":"crossref","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. (2010). Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol, 68:18-27.","DOI":"10.1002\/ana.22060"},{"key":"key-10.14336\/AD.2020.1225-68","doi-asserted-by":"crossref","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, et al. (2016). Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol, 15:154-165.","DOI":"10.1016\/S1474-4422(15)00336-1"},{"key":"key-10.14336\/AD.2020.1225-69","doi-asserted-by":"crossref","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. (2017). Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol, 74:197-206.","DOI":"10.1001\/jamaneurol.2016.4703"},{"key":"key-10.14336\/AD.2020.1225-70","doi-asserted-by":"crossref","unstructured":"Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al. (2018). Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology, 90:e1849-e1857.","DOI":"10.1212\/WNL.0000000000005557"},{"key":"key-10.14336\/AD.2020.1225-71","doi-asserted-by":"crossref","unstructured":"Parkinson Study G (1993). Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med, 328:176-183.","DOI":"10.1056\/NEJM199301213280305"},{"key":"key-10.14336\/AD.2020.1225-72","doi-asserted-by":"crossref","unstructured":"Ward CD (1994). Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry, 57:217-220.","DOI":"10.1136\/jnnp.57.2.217"},{"key":"key-10.14336\/AD.2020.1225-73","doi-asserted-by":"crossref","unstructured":"Parkinson Study G (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol, 62:241-248.","DOI":"10.1001\/archneur.62.2.241"},{"key":"key-10.14336\/AD.2020.1225-74","doi-asserted-by":"crossref","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. (2005). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet, 365:947-954.","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"key-10.14336\/AD.2020.1225-75","doi-asserted-by":"crossref","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med, 361:1268-1278.","DOI":"10.1056\/NEJMoa0809335"},{"key":"key-10.14336\/AD.2020.1225-76","doi-asserted-by":"crossref","unstructured":"Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. (2006). Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, 67:S18-23.","DOI":"10.1212\/WNL.67.7_suppl_2.S18"},{"key":"key-10.14336\/AD.2020.1225-77","doi-asserted-by":"crossref","unstructured":"Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. (2017). Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol, 74:216-224.","DOI":"10.1001\/jamaneurol.2016.4467"},{"key":"key-10.14336\/AD.2020.1225-78","doi-asserted-by":"crossref","unstructured":"Hong CT, Chan L, Wu D, Chen WT, Chien LN (2019). Antiparkinsonism anticholinergics increase dementia risk in patients with Parkinson's disease. Parkinsonism Relat Disord, 65:224-229.","DOI":"10.1016\/j.parkreldis.2019.06.022"},{"key":"key-10.14336\/AD.2020.1225-79","doi-asserted-by":"crossref","unstructured":"Rajan R, Saini A, Verma B, Choudhary N, Gupta A, Vishnu VY, et al. (2020). Anticholinergics May Carry Significant Cognitive and Gait Burden in Parkinson's Disease. Movement Disorders Clinical Practice, 7:803-809.","DOI":"10.1002\/mdc3.13032"},{"key":"key-10.14336\/AD.2020.1225-80","doi-asserted-by":"crossref","unstructured":"Schwab RS, England ACJr, Poskanzer DC, Young RR (1969). Amantadine in the treatment of Parkinson's disease. JAMA, 208:1168-1170.","DOI":"10.1001\/jama.208.7.1168"},{"key":"key-10.14336\/AD.2020.1225-81","doi-asserted-by":"crossref","unstructured":"Kuhn W, M\u00fcller T2020. Amantadine for Treating Parkinson\u2019s Disease. In NeuroPsychopharmacotherapy. RiedererP, LauxG, MulsantB, LeW, and NagatsuT, editors. Cham: Springer International Publishing. 1-6.","DOI":"10.1007\/978-3-319-56015-1_220-1"},{"key":"key-10.14336\/AD.2020.1225-82","doi-asserted-by":"crossref","unstructured":"Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, et al. (2019). Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet, 58:77-88.","DOI":"10.1007\/s40262-018-0663-4"},{"key":"key-10.14336\/AD.2020.1225-83","doi-asserted-by":"crossref","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. (2017). ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. JAMA Neurol, 74:941-949.","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"key-10.14336\/AD.2020.1225-84","doi-asserted-by":"crossref","unstructured":"Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009). Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord, 15:406-413.","DOI":"10.1016\/j.parkreldis.2008.12.006"},{"key":"key-10.14336\/AD.2020.1225-85","doi-asserted-by":"crossref","unstructured":"Mizuno Y, Kondo T, Japanese Istradefylline Study G (2013). Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov Disord, 28:1138-1141.","DOI":"10.1002\/mds.25418"},{"key":"key-10.14336\/AD.2020.1225-86","doi-asserted-by":"crossref","unstructured":"Takahashi M, Fujita M, Asai N, Saki M, Mori A (2018). Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother, 19:1635-1642.","DOI":"10.1080\/14656566.2018.1518433"},{"key":"key-10.14336\/AD.2020.1225-87","doi-asserted-by":"crossref","unstructured":"Ferrari A, Manca M, Tugnoli V, Alberto L (2018). Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal. Funct Neurol, 33:7-18.","DOI":"10.11138\/FNeur\/2018.33.1.007"},{"key":"key-10.14336\/AD.2020.1225-88","doi-asserted-by":"crossref","unstructured":"Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG (2006). Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord, 21:704-707.","DOI":"10.1002\/mds.20793"},{"key":"key-10.14336\/AD.2020.1225-89","doi-asserted-by":"crossref","unstructured":"Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, et al. (2003). Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord, 18:685-688.","DOI":"10.1002\/mds.10420"},{"key":"key-10.14336\/AD.2020.1225-90","doi-asserted-by":"crossref","unstructured":"Giladi N, Meer J, Honigman S (1994). The use of botulinum toxin to treat \"striatal\" toes. J Neurol Neurosurg Psychiatry, 57:659.","DOI":"10.1136\/jnnp.57.5.659"},{"key":"key-10.14336\/AD.2020.1225-91","doi-asserted-by":"crossref","unstructured":"Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G (1995). \"Off\" painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord, 10:333-336.","DOI":"10.1002\/mds.870100317"},{"key":"key-10.14336\/AD.2020.1225-92","doi-asserted-by":"crossref","unstructured":"Azher SN, Jankovic J (2005). Camptocormia: pathogenesis, classification, and response to therapy. Neurology, 65:355-359.","DOI":"10.1212\/01.wnl.0000171857.09079.9f"},{"key":"key-10.14336\/AD.2020.1225-93","doi-asserted-by":"crossref","unstructured":"Fietzek UM, Schroeteler FE, Ceballos-Baumann AO (2009). Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord, 24:2027-2028.","DOI":"10.1002\/mds.22676"},{"key":"key-10.14336\/AD.2020.1225-94","doi-asserted-by":"crossref","unstructured":"Anderson RU, Orenberg EK, Glowe P (2014). OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology, 83:22-27.","DOI":"10.1016\/j.urology.2013.09.017"},{"key":"key-10.14336\/AD.2020.1225-95","doi-asserted-by":"crossref","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. (2018). International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord, 33:1248-1266.","DOI":"10.1002\/mds.27372"},{"key":"key-10.14336\/AD.2020.1225-96","doi-asserted-by":"crossref","unstructured":"Mak MK, Wong-Yu IS, Shen X, Chung CL (2017). Long-term effects of exercise and physical therapy in people with Parkinson disease. Nat Rev Neurol, 13:689-703.","DOI":"10.1038\/nrneurol.2017.128"},{"key":"key-10.14336\/AD.2020.1225-97","doi-asserted-by":"crossref","unstructured":"Yang Y, Li XY, Gong L, Zhu YL, Hao YL (2014). Tai Chi for improvement of motor function, balance and gait in Parkinson's disease: a systematic review and meta-analysis. PLoS One, 9:e102942.","DOI":"10.1371\/journal.pone.0102942"},{"key":"key-10.14336\/AD.2020.1225-98","doi-asserted-by":"crossref","unstructured":"Zhang S, Liu D, Ye D, Li H, Chen F (2017). Can music-based movement therapy improve motor dysfunction in patients with Parkinson's disease? Systematic review and meta-analysis. Neurol Sci, 38:1629-1636.","DOI":"10.1007\/s10072-017-3020-8"},{"key":"key-10.14336\/AD.2020.1225-99","doi-asserted-by":"crossref","unstructured":"Delgado-Alvarado M, Marano M, Santurtun A, Urtiaga-Gallano A, Tordesillas-Gutierrez D, Infante J (2020). Nonpharmacological, nonsurgical treatments for freezing of gait in Parkinson's disease: A systematic review. Mov Disord, 35:204-214.","DOI":"10.1002\/mds.27913"},{"key":"key-10.14336\/AD.2020.1225-100","doi-asserted-by":"crossref","unstructured":"McCandless PJ, Evans BJ, Janssen J, Selfe J, Churchill A, Richards J (2016). Effect of three cueing devices for people with Parkinson's disease with gait initiation difficulties. Gait Posture, 44:7-11.","DOI":"10.1016\/j.gaitpost.2015.11.006"},{"key":"key-10.14336\/AD.2020.1225-101","doi-asserted-by":"crossref","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. (2019). Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord, 34:180-198.","DOI":"10.1002\/mds.27602"},{"key":"key-10.14336\/AD.2020.1225-102","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. (2004). Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med, 351:2509-2518.","DOI":"10.1056\/NEJMoa041470"},{"key":"key-10.14336\/AD.2020.1225-103","doi-asserted-by":"crossref","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. (2014). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 383:533-540.","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"key-10.14336\/AD.2020.1225-104","doi-asserted-by":"crossref","unstructured":"Palma JA, Kaufmann H (2018). Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord, 33:372-390.","DOI":"10.1002\/mds.27344"},{"key":"key-10.14336\/AD.2020.1225-105","doi-asserted-by":"crossref","unstructured":"Eusebio A, Thevathasan W, Doyle Gaynor L, Pogosyan A, Bye E, Foltynie T, et al. (2011). Deep brain stimulation can suppress pathological synchronisation in parkinsonian patients. J Neurol Neurosurg Psychiatry, 82:569-573.","DOI":"10.1136\/jnnp.2010.217489"},{"key":"key-10.14336\/AD.2020.1225-106","doi-asserted-by":"crossref","unstructured":"Herrington TM, Cheng JJ, Eskandar EN (2016). Mechanisms of deep brain stimulation. J Neurophysiol, 115:19-38.","DOI":"10.1152\/jn.00281.2015"},{"key":"key-10.14336\/AD.2020.1225-107","doi-asserted-by":"crossref","unstructured":"Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, et al. (2012). Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol, 11:140-149.","DOI":"10.1016\/S1474-4422(11)70308-8"},{"key":"key-10.14336\/AD.2020.1225-108","doi-asserted-by":"crossref","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, et al. (2006). A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med, 355:896-908.","DOI":"10.1056\/NEJMoa060281"},{"key":"key-10.14336\/AD.2020.1225-109","doi-asserted-by":"crossref","unstructured":"Lachenmayer ML, Bettschen C, Bernasconi C, Petermann K, Debove I, Muellner J, et al. (2019). Stimulation of the globus pallidus internus in the treatment of Parkinson's disease: Long-term results of a monocentric cohort. Parkinsonism Relat Disord, 64:118-123.","DOI":"10.1016\/j.parkreldis.2019.03.009"},{"key":"key-10.14336\/AD.2020.1225-110","doi-asserted-by":"crossref","unstructured":"Limousin P, Foltynie T (2019). Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol, 15:234-242.","DOI":"10.1038\/s41582-019-0145-9"},{"key":"key-10.14336\/AD.2020.1225-111","unstructured":"Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, et al. (2013). Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med, 368:610-622."},{"key":"key-10.14336\/AD.2020.1225-112","doi-asserted-by":"crossref","unstructured":"Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, et al. (2013). Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol, 12:37-44.","DOI":"10.1016\/S1474-4422(12)70264-8"},{"key":"key-10.14336\/AD.2020.1225-113","doi-asserted-by":"crossref","unstructured":"Ramirez-Zamora A, Ostrem JL (2018). Globus Pallidus Interna or Subthalamic Nucleus Deep Brain Stimulation for Parkinson Disease: A Review. JAMA Neurol, 75:367-372.","DOI":"10.1001\/jamaneurol.2017.4321"},{"key":"key-10.14336\/AD.2020.1225-114","doi-asserted-by":"crossref","unstructured":"Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med, 362:2077-2091.","DOI":"10.1056\/NEJMoa0907083"},{"key":"key-10.14336\/AD.2020.1225-115","doi-asserted-by":"crossref","unstructured":"Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, et al. (2011). Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol, 68:165.","DOI":"10.1001\/archneurol.2010.260"},{"key":"key-10.14336\/AD.2020.1225-116","doi-asserted-by":"crossref","unstructured":"Videnovic A, Metman LV (2008). Deep brain stimulation for Parkinson's disease: prevalence of adverse events and need for standardized reporting. Mov Disord, 23:343-349.","DOI":"10.1002\/mds.21753"},{"key":"key-10.14336\/AD.2020.1225-117","doi-asserted-by":"crossref","unstructured":"Okun MS (2019). Tips for Choosing a Deep Brain Stimulation Device. JAMA Neurol, 76:749-750.","DOI":"10.1001\/jamaneurol.2019.0849"},{"key":"key-10.14336\/AD.2020.1225-118","doi-asserted-by":"crossref","unstructured":"Paff M, Loh A, Sarica C, Lozano AM, Fasano A (2020). Update on Current Technologies for Deep Brain Stimulation in Parkinson's Disease. J Mov Disord, 13:185-198.","DOI":"10.14802\/jmd.20052"},{"key":"key-10.14336\/AD.2020.1225-119","doi-asserted-by":"crossref","unstructured":"Wirdefeldt K, Odin P, Nyholm D (2016). Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. CNS Drugs, 30:381-404.","DOI":"10.1007\/s40263-016-0336-5"},{"key":"key-10.14336\/AD.2020.1225-120","doi-asserted-by":"crossref","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, et al. (2013). Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. AAPS J, 15:316-323.","DOI":"10.1208\/s12248-012-9439-1"},{"key":"key-10.14336\/AD.2020.1225-121","doi-asserted-by":"crossref","unstructured":"Wang L, Li J, Chen J (2018). Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol, 9:620.","DOI":"10.3389\/fneur.2018.00620"},{"key":"key-10.14336\/AD.2020.1225-122","doi-asserted-by":"crossref","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs, et al. (2015). Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord, 21:231-235.","DOI":"10.1016\/j.parkreldis.2014.12.012"},{"key":"key-10.14336\/AD.2020.1225-123","doi-asserted-by":"crossref","unstructured":"Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, et al. (2017). Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract, 4:829-837.","DOI":"10.1002\/mdc3.12526"},{"key":"key-10.14336\/AD.2020.1225-124","doi-asserted-by":"crossref","unstructured":"Merola A, Romagnolo A, Zibetti M, Bernardini A, Cocito D, Lopiano L (2016). Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol, 23:501-509.","DOI":"10.1111\/ene.12846"},{"key":"key-10.14336\/AD.2020.1225-125","doi-asserted-by":"crossref","unstructured":"Liu XD, Bao Y, Liu GJ (2019). Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol, 10:934.","DOI":"10.3389\/fneur.2019.00934"},{"key":"key-10.14336\/AD.2020.1225-126","doi-asserted-by":"crossref","unstructured":"Valldeoriola F, Santacruz P, Rios J, Compta Y, Rumia J, Munoz JE, et al. (2017). l-Dopa\/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior. Brain Behav, 7:e00848.","DOI":"10.1002\/brb3.848"},{"key":"key-10.14336\/AD.2020.1225-127","doi-asserted-by":"crossref","unstructured":"Bond AE, Shah BB, Huss DS, Dallapiazza RF, Warren A, Harrison MB, et al. (2017). Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol, 74:1412-1418.","DOI":"10.1001\/jamaneurol.2017.3098"},{"key":"key-10.14336\/AD.2020.1225-128","doi-asserted-by":"crossref","unstructured":"Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, et al. (2016). A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor. N Engl J Med, 375:730-739.","DOI":"10.1056\/NEJMoa1600159"},{"key":"key-10.14336\/AD.2020.1225-129","doi-asserted-by":"crossref","unstructured":"Martinez-Fernandez R, Rodriguez-Rojas R, Del Alamo M, Hernandez-Fernandez F, Pineda-Pardo JA, Dileone M, et al. (2018). Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study. Lancet Neurol, 17:54-63.","DOI":"10.1016\/S1474-4422(17)30403-9"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/ad-0-0-0-2012281010-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T01:29:06Z","timestamp":1627522146000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2020.1225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":129,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2020.1225","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}